RU 486 BEING TESTED AS POSTCOITAL CONTRACEPTIVE
Executive Summary
RU 486 BEING TESTED AS POSTCOITAL CONTRACEPTIVE in a trial that will enroll 150 women in the San Francisco Bay Area, the University of California-San Francisco announced May 3. Under an IND approved by FDA, the women will receive the antiprogestin mifepristone as an emergency "morning-after pill." The study is part of a larger 2,100-patient trial being sponsored by the World Health Organization at 14 sites worldwide.